Peptide Receptor Radionuclide Therapy (PRRT)

PRRT Trials

• Alpha PRRT with Pb-212 (all NET)

• Alpha PRRT with Ac-225 (GEP-NETs only)

• Alpha PRRT with Ac-225 + Standard of Care in SSTR+ SCLC 

• COMPOSE (GEP-NETs)

• Alpha PRRT with Pb-212 VMT

• ComPareNET Lu-177 vs CAPTEM in PNETs

• Lu-177 + Carboplatin, Etoposide, and Atezolizumab in SCLC

• Lu-177 DOTATATE + Cabozantanib (all NET)

• Lu-177 DOTATATE + M3814 (Peposertib)  (GEP-NETs)

• Lu-177 DOTATATE + Olaparib  (GEP-NETs)

• Lu-177 DOTATATE + Sunitinib in PNETs

• Lu-177 DOTATATE + Triapine in GEP-NETs

• Lu-177 DOTATATE vs Everolimus in Lung NETs

• NETTER-P: Lutathera in Adolescent Patients 

• NET RETREAT of Lu-177 Retreatment vs Everolimus in Midgut NET

Alpha PRRT Trials

• Alpha PRRT with Pb-212 (all NET)

• Alpha PRRT with Ac-225 (GEP-NETs only)

• Alpha PRRT with Ac-225 + Standard of Care in SSTR+ SCLC 

• Alpha PRRT with Pb-212 VMT

Combo Trial with Lu177 + Additional Medication

• Lu177 DOTATATE + M3814 (Peposertib)  (GEP-NETs)

• Lu177 DOTATATE + Olaparib  (GEP-NETs)

• Lu-177 DOTATATE + Triapine in GEP-NETs

• Lu177 DOTATATE + Cabozantanib (all NET)

• Lu-177 DOTATATE + Sunitinib in PNETs

PRRT for Specific Populations

• Alpha PRRT with Ac-225 + Standard of Care in SSTR+ SCLC 

• Lu-177 + Carboplatin, Etoposide, and Atezolizumab in SCLC

• Lu-177 DOTATATE vs Everolimus in Lung NETs

• NETTER-P: Lutathera in Adolescent Patients 

PRRT Comparison Trial of Lu177 versus Another Medication 

• COMPOSE (GEP-NETs)

• ComPareNET Lu-177 vs CAPTEM in PNETs